EDSA News and Press, Edesa Biotech Inc. From 06/15/20

Are These Penny Stocks To Buy Or Avoid This Week? When it comes to penny stocks , things can change at a moment’s notice. We saw this first-hand over the last few days. On Friday, there were several stocks under $5 that finished the week strong. But if you were to look at them on Monda...

Edesa Biotech (NASDAQ: EDSA ) is up  160%  premarket after receiving expedited approval from Health Canada to begin a Phase 2/3 clinical study of its investigational drug, EB05, as a potential treatment for moderate to severe COVID-19 patients. More news on: Edesa Biotech, Inc....

TORONTO, ON / ACCESSWIRE / June 15, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received expedited approval from Health Canada to begin a Phase 2/3 clinical study of its investigational drug, EB05, which the company is developing as a potential t...

Edesa Biotech (NASDAQ: EDSA ): Q2 GAAP EPS of -$0.17 misses by $0.05 . More news on: Edesa Biotech, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

TORONTO, ON / ACCESSWIRE / May 15, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended March 31, 2020 and provided an update on its business. Edesa reported that two new biologic drug candi...

Thinly traded nano cap Edesa Biotech ( EDSA +21.1% ) inks an agreement with Swiss firm Light Chain Bioscience for exclusive global rights to two Phase 2-ready biologic candidates that, it says, may show efficacy in COVID-19 patients with acute respiratory distress syndrome and lung injur...

TORONTO, ON / ACCESSWIRE / April 20, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced a strategic agreement with Light Chain Bioscience (a brand of NovImmune SA), a leading Swiss pharmaceutical development company, for an exclusive worldwi...

TORONTO, ON / ACCESSWIRE / March 12, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced a collaborative research project with the National Research Council of Canada (NRC) to develop novel immunotherapies for vitiligo as well as other indica...

Edesa Biotech (NASDAQ: EDSA ): Q1 GAAP EPS of -$0.15. More news on: Edesa Biotech, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

TORONTO, ON / ACCESSWIRE / February 13, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three months ended December 31, 2019 and provided an update on its business. During the quarter, Edesa expanded an ongoing P...